We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Identifying Shared Genetic Susceptibility Regions in Chronic Beryllium Disease and Sarcoidosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00560989
Recruitment Status : Completed
First Posted : November 20, 2007
Last Update Posted : September 26, 2014
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by:
National Jewish Health

November 16, 2007
November 20, 2007
September 26, 2014
March 2007
Not Provided
Shared genetic regions associated with the risk of the granulomatous diseases CBD and sarcoidosis [ Time Frame: Measured at completion of genetic analysis ]
Same as current
Complete list of historical versions of study NCT00560989 on ClinicalTrials.gov Archive Site
Genetic/chromosomal regions associated with CBD and sarcoidosis [ Time Frame: Measured at completion of genetic analysis ]
Same as current
Not Provided
Not Provided
Identifying Shared Genetic Susceptibility Regions in Chronic Beryllium Disease and Sarcoidosis
Shared Genetic Susceptibility in CBD and Sarcoidosis
Granulomatous lung diseases are diseases in which inflamed clusters of white cells, known as granulomas, form in lung tissue. Chronic beryllium disease (CBD) and sarcoidosis are two granulomatous diseases that share similar clinical symptoms, physiological changes in the lungs, and immune responses to the disease. Genetic variations may make some people more susceptible to developing CBD or sarcoidosis. This study will identify common genetic regions associated with increased risk of developing the granulomatous diseases CBD and sarcoidosis.

CBD and sarcoidosis are granulomatous lung diseases that are caused by an abnormal immune response. While CBD is known to develop from exposure to the industrial product beryllium, the cause of sarcoidosis remains undetermined. CBD occurs in 2 to 16% of people exposed to beryllium and varies in severity of symptoms. People with sarcoidosis often show very minor symptoms. However, certain variables have been associated with the more severe forms of disease. These variables include black race, onset over the age of 40, involvement of more than three affected organs, and presence of more serious lung disease. When serious symptoms of sarcoidosis occur, clinical and pathological appearances of CBD and sarcoidosis are often hard to distinguish. Symptoms common to both diseases include fever, chest pain, weight loss, night sweats, fatigue, and presence of granulomas on the lungs. The fact that the severity of both diseases varies greatly among those affected points to possible genetic involvement. The genetic basis being analyzed in this study begins with the similar immune responses in the development of both diseases, specifically involving human leukocyte antigen (HLA) gene products. The purpose of this study is to identify common genetic regions associated with increased risk of developing the granulomatous diseases CBD and sarcoidosis.

This study will utilize a novel technique, known as a genome-wide scan. The study will examine previously collected DNA samples from participants in a previous NIH study, A Case Control Etiologic Study of Sarcoidosis (ACCESS), and from participants with CBD recruited at the National Jewish Medical and Research Center. Using the genome scans, researchers will compare genetic regions of people with CBD versus people without CBD who have been exposed to beryllium. The same approach will be used to define genetic regions associated with sarcoidosis. Genome control methods will be used to account for population stratification in both the CBD and sarcoidosis populations. Researchers will compare data between diseased and healthy control groups and between CBD and sarcoidosis groups to identify shared genetic regions relevant to disease development. A second genome scan involving two larger populations of CBD and sarcoidosis cases and controls will be conducted to confirm the association of these regions with both diseases.

Observational Model: Case Control
Time Perspective: Retrospective
Not Provided
Retention:   Samples With DNA
DNA specimens
Non-Probability Sample
This study will use specimens from two well-established disease popultions: a CBD population previously recruited at the National Jewish Medical and Research Center and a sarcoidosis population derived from the previous NHLBI study, A Case-Control Etiologic Study of Sarcoidosis (ACCESS).
  • Sarcoidosis
  • Berylliosis
Not Provided
  • 1
    CBD cases
  • 2
    Beryllium-exposed, non-diseased control subjects
  • 3
    Sarcoidosis cases
  • 4
    Sarcoidosis control subjects
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
March 2007
Not Provided

Inclusion Criteria:

  • Has previously participated in beryllium studies conducted by Dr. Lisa Maier
  • Agrees to allow the use of personal medical records and genetic material for future research by study officials

Exclusion Criteria:

  • Will not consent for use of DNA for research purposes or for storage
  • Any beryllium or sarcoidosis DNA specimens without an optical density of 260/280 nm, ratio between 1.8 and 2.0, or with an insufficient quantity of DNA for analysis purposes
Sexes Eligible for Study: All
18 Years to 80 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
R21HL081766 ( U.S. NIH Grant/Contract )
R21HL081766-01A2 ( U.S. NIH Grant/Contract )
Not Provided
Not Provided
Not Provided
National Jewish Health
National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigator: Lisa A. Maier, MD, MSPH National Jewish Health
National Jewish Health
September 2014